NewsBenzingaOS Therapies achève la requalification de la substance active Herlystic de phase 2b pour l’essai de confirmation de phase 3 OS Therapies achève la requalification de la substance active Herlystic de phase 2b pour l’essai de confirmation de phase 3 Benzinga 2026.11.05 13:14 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Maintains Hold on Skydance, Lowers Price Target to $8.5 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84